Can immune booster cells revive failing CAR-T therapy in leukemia?
NCT ID NCT06389305
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 213 participants will be randomly assigned to receive either control cells, CIK cells, or enhanced mRNA-CIK cells. The main goal is to see if CIK therapy improves how long patients stay free of relapse or treatment failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can we make CAR-T cells last longer in leukemia?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot